Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Compare the viral load of hepatitis c virus in patients converted to certican versus patients who are maintained on calcineurin inhibitor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prospective, Open Label Study of CERtican in KIdney Transplantation

NCT01594268

Kidney Transplant

COMPLETED PHASE4

Efficacy of Certican® in Combination With Myfortic® in Renal

NCT01399242

UNKNOWN PHASE4

Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion

NCT00443508

Kidney Diseases

UNKNOWN PHASE4

Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation

NCT00710801

Hepatitis C Virus

COMPLETED

Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

NCT00634920

Renal Function

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The infection by hepatitis C virus (HCV) is the leading cause of chronic liver disease in renal transplant recipients.

The prevalence of pretransplantation anti-HCV is 11% to 49%. The impact of HCV infection on patient survival after renal transplant remains controversial. Some studies also showed that patients undergoing renal transplantation anti-HCV positive are associated with a reduction in graft and patient survival.Chronic infection of HCV is associated with an increased number of infections.

In HCV positive renal transplant patients have been shown that there is an increase from four to seven times in HCV viremia after transplantation compared to pretransplant.

To prevent viral replication, immunosuppression must be adapted, involving a balance between control of viral replication and rejection.

Biochemically, the NS5A protein has been linked to increased replication of the hepatitis C virus through p70S6K phosphopeptides. Sirolimus as inhibitor of pathway mTOR/p70S6K reduced in vivo phosphorylation of NS5A phosphopeptides and thus viral replication. Moreover, the mTOR protein has been proven in vitron to have a protective role against apoptosis in HCV infected cells (WAGNER et al., 2010).

Wagner et al. (2010) showed a beneficial effect of sirolimus on viral recurrence monitored by transaminases and viral load as well as by histological data. They also reported the improved survival after liver transplantation due to hepatitis C for patients receiving sirolimus rather than calcineurin inhibitor-based regimens.

In the literature there have already been reported good virological control of HCV among liver transplant recipients after conversion to SRL and the reduction of hepatitis C virus recurrence (GALLEGO et al., 2009; BENEDETTOET al., 2010).

Everolimus has shown a potent inhibitor of mTOR and has been widely used as an immunosuppressive agent in kidney transplant, but no reported effects on HCV progression was found in the literature.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Allograft Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Certican®

Arm1(conversion):Certican®+mycophenolate+prednisone

Group Type EXPERIMENTAL

Everolimus

Intervention Type DRUG

The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.

Tacrolimus or Cyclosporine

Arm2(maintained):Tacrolimus or Cyclosporine+mycophenolate+prednisone

Group Type ACTIVE_COMPARATOR

Cyclosporine

Intervention Type DRUG

Trough level should be between 100 and 200ng/ml.

Tacrolimus

Intervention Type DRUG

Trough level should be between 5 and 10ng/ml.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Everolimus

The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.

Intervention Type DRUG

Cyclosporine

Trough level should be between 100 and 200ng/ml.

Intervention Type DRUG

Tacrolimus

Trough level should be between 5 and 10ng/ml.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years at the time of screening;
* Subjects between the first and tenth year after renal transplantation;
* Subjects with positive serology for hepatitis C;
* Subjects receiving calcineurin inhibitor (tacrolimus or cyclosporine) plus mycophenolate sodium or mofetil plus prednisone since the first month post-transplant;
* Subjects with no acute rejection episode in the last 3 month;
* Women of childbearing potential (CBP) with a negative pregnancy test at screening (urine or serum;
* Women of CBP and men with sexual partners of CBP must agree to use a medically acceptable method of contraception throughout the study. The investigator will determine which contraceptive method more effective and appropriate for each study subject. Acceptable methods of contraception include oral contraceptives, barrier methods (eg, diaphragm or condom with spermicide) and intrauterine devices.

Exclusion Criteria

* Subjects who, in the opinion of the investigator, are not able to complete the study;
* Recipients of multiple organ transplant (i.e., prior or concurrent transplantation of a non-renal allograft;
* Subjects with a calculated GFR \< 30ml/min (abbreviated MDRD formula;
* Subjects with Urinary protein/creatinine \> 0.5;
* Renal biopsy with score ≥ Banff grade II interstitial fibrosis and tubular atrophy (Banff 2007;
* Subjects with a history of biopsy-proven acute rejection within 12 weeks of enrollment;
* Known or suspected hypersensitivity to inhibitor of mTOR;
* Subjects with a history of primary or recurrent FSGS, membranous glomerulonephritis (MGN) or membranoproliferative glomerulonephritis (MPGN);
* Evidence of any active systemic or localized major infection;
* Use of any investigational drug or treatment up to 4 weeks before enrollment;
* Immunosuppressive therapies other than those described by this protocol;
* Planned systemic treatment with voriconazole, cisapride or ketoconazole that will not be discontinued before randomization;
* Prior treatment with aminoglycosides, amphotericin B, cisplatin or other drugs associated with renal dysfunction that is not discontinued before screening;
* Subjects with a screening total white blood cell count (WBC) ≤ 2000/mm3, hemoglobin ≤ 10g/dL and platelet count ≤ 100000/mm3;
* TGO/AST, TGP/ALT and bilirubins with values three times higher than reference values;
* Fasting triglycerides ≥ 400 mg/dL, fasting total cholesterol ≥ 350 mg/dL or LDL-cholesterol ≥ 160mg/dL despite the use of optimal lipid-lowering therapy;
* History of malignancy within 3 years before enrollment other than adequately treated basal cell or squamous cell carcinoma of the skin;
* Subjects who are known to be human immunodeficiency virus (HIV) positive or hepatitis B positive;
* Chronic hepatic failure.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Valter Duro Garcia

PHYSICIAN NEPHROLOGY

Responsibility Role PRINCIPAL_INVESTIGATOR